| 4407-3 |
Primidone |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Primidone [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4407-3 |
|
|
|
|
Observation |
|
|
|
0 |
Primidone Dose |
|
|
|
Y |
|
Dose med or substance; DRUG DOSES; Mysoline; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 44070-1 |
Cells.CD20+CD52+/Cells |
NFr |
Bone mar |
Pt |
Qn |
|
|
ACTIVE |
CD20+CD52+ cells/cells in Bone marrow |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
44070-1 |
|
|
|
|
Both |
|
|
|
0 |
CD20+CD52+ Cells NFr Mar |
|
|
|
N |
|
B1; B-1; BM; BON; Bone marrow; Bp35; CD20 Cells; CD20+CD52+ Cells; Cell; CELL MARKERS; Cellularity; Leu16; Leu-16; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.17 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 44071-9 |
Cells.CD20+CD52+/Cells |
NFr |
CSF |
Pt |
Qn |
|
|
ACTIVE |
CD20+CD52+ cells/cells in Cerebral spinal fluid |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
44071-9 |
|
|
|
|
Both |
|
|
|
0 |
CD20+CD52+ Cells NFr CSF |
|
|
|
N |
|
B1; B-1; Bp35; CD20 Cells; CD20+CD52+ Cells; Cell; CELL MARKERS; Cellularity; Cerebral spinal fluid; Cerebrospinal Fl; Leu16; Leu-16; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.79 |
2.17 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 44072-7 |
Cells.CD20+CD52+/Cells |
NFr |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
CD20+CD52+ cells/cells in Body fluid |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
44072-7 |
|
|
|
|
Both |
|
|
|
0 |
CD20+CD52+ Cells NFr Fld |
|
|
|
N |
|
B/F; B1; B-1; BF; bod; Bodies; Body fluid; Body fluid, unsp; Bp35; CD20 Cells; CD20+CD52+ Cells; Cell; CELL MARKERS; Cellularity; Fl; Fld; FLU; Fluid; Leu16; Leu-16; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.17 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 44073-5 |
Cells.CD20+CD52+/Cells |
NFr |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
CD20+CD52+ cells/cells in Tissue |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
44073-5 |
|
|
|
|
Both |
|
|
|
0 |
CD20+CD52+ Cells NFr Tiss |
|
|
|
N |
|
B1; B-1; Bp35; CD20 Cells; CD20+CD52+ Cells; Cell; CELL MARKERS; Cellularity; Leu16; Leu-16; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.79 |
2.17 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 44074-3 |
Arbovirus Ab |
Imp |
Ser |
Pt |
Nom |
IF |
|
ACTIVE |
Arbovirus Ab [Interpretation] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44074-3 |
|
IF |
|
|
Observation |
|
|
|
0 |
Arbovirus Ab Ser IF-Imp |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbo virus; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Point in time; Random; Serum; SR; Time Resolved Fluorescence; TRF |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44075-0 |
Bilirubin casts |
PrThr |
Urine sed |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Bilirubin casts [Presence] in Urine sediment by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
44075-0 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Bilirubin Casts UrnS Ql Micro |
|
|
|
N |
|
Bili; Bilirubins; Billirubin; Cast; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; TBIL; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 44076-8 |
Alpha tocopherol & Beta+gamma tocopherol |
Imp |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Alpha tocopherol and Beta+gamma tocopherol [Interpretation] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44076-8 |
|
|
|
|
Observation |
|
|
|
0 |
A & B+G Tocopherol SerPl-Imp |
|
|
|
N |
|
A & B+G Tocopherol; Alfa; A-Tocopherol Vit E; B; Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tocopherols; Vit E; Vitamin E |
2.52 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44077-6 |
Brucella canis Ab.IgG & IgM |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Brucella canis IgG and IgM [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44077-6 |
|
|
|
|
Observation |
|
|
|
0 |
B canis IgG+IgM Ser-Imp |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B canis; Bruc; Brucellosis; ID; IgG+IgM; Immune globulin G; Immune globulin M; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Point in time; Random; Serum; SR |
2.38 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44078-4 |
Catecholamines |
Imp |
Urine |
Pt |
Nom |
|
|
ACTIVE |
Catecholamines [Interpretation] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44078-4 |
|
|
|
|
Observation |
|
|
|
0 |
Catechols Ur-Imp |
|
|
|
N |
|
Cate; Catec; Catech; Catechol; Catecholamine; Catecholamines.total; Catechols; Chemistry; Epinephrine+norepinephrine+dopamine; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random; UA; UR; Urn |
2.5 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44079-2 |
Chlamydia trachomatis Ab.IgA & IgG & IgM |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Chlamydia trachomatis IgA and IgG and IgM [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44079-2 |
|
|
|
|
Observation |
|
|
|
0 |
C trach IgA+IgG+IgM Ser-Imp |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; ID; IgA+IgG; IgA+IgG+IgM; Immune globulin A; Immune globulin G; Immune globulin M; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; LGV; Lymphogranuloma venereum; Microbiology; Nominal; Point in time; Random; Serum; SR; Trachoma |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4408-1 |
Probenecid |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Probenecid [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4408-1 |
|
|
|
|
Observation |
|
|
|
0 |
Probenecid Dose |
|
|
|
Y |
|
Benemid; Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 44080-0 |
Chlamydophila pneumoniae Ab.IgG & IgM |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Chlamydophila pneumoniae IgG and IgM [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44080-0 |
|
|
|
|
Observation |
|
|
|
0 |
C pneum IgG+IgM Ser-Imp |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; C pneum; C pneumo; C pneumoniae; Chlamydia; Chlamydia pneumoniae; CPN; ID; IgG+IgM; Immune globulin G; Immune globulin M; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Pneu; pneum; Pneumo; Pneumon; Pneumonia; Point in time; Random; Serum; SR; Twar agent |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44081-8 |
Chlamydophila psittaci Ab.IgA & IgG & IgM |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44081-8 |
|
|
|
|
Observation |
|
|
|
0 |
C psittaci IgA+IgG+IgM Ser-Imp |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Avian chlamydiosis; C psittaci; Chlamydia; Chlamydia psittaci; Chlamydial abortion; CPS; Enzootic abortion of ewes; ID; IgA+IgG; IgA+IgG+IgM; Immune globulin A; Immune globulin G; Immune globulin M; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Ornithosis; Ovine chlamydiosis; Point in time; Psittacosis; Random; Serum; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44082-6 |
Cryoglobulin IgA & IgG & IgM |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Cryoglobulin IgA and IgG and IgM [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44082-6 |
|
|
|
|
Observation |
|
|
|
0 |
Cryoglob IgA & IgG & IgM Ser-Imp |
|
|
|
N |
|
Chemistry; Cryo; Cryoglob IgA; Cryoglob IgA & IgG & IgM; Cryoglobulins; Cryoprecipitate; Immune globulin A; Immune globulin G; Immune globulin M; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random; Serum; SR |
2.38 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44083-4 |
Extractable nuclear Ab |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Extractable nuclear Ab [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
44083-4 |
|
|
|
|
Observation |
|
|
|
0 |
ENA Ab Ser-Imp |
|
|
|
N |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; ENA; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; NA; Nominal; Nuc; Point in time; Random; Serology; Serum; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44084-2 |
Fatty acids pattern |
Imp |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Fatty acids pattern [Interpretation] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44084-2 |
|
|
|
|
Observation |
|
|
|
0 |
Fatty acids pattern SerPl-Imp |
|
|
|
N |
|
Acd; Acid; Chemistry; Fatty acid; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Lipid; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44085-9 |
Xylose absorption |
Imp |
Urine+Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Xylose absorption [Interpretation] in Urine and Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
44085-9 |
|
|
|
|
Observation |
|
|
|
0 |
Xylose Absorption Ur+SerPl-Imp |
|
|
|
N |
|
Absorp; CHEMISTRY.CHALLENGE TESTING; D-xylose; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UA; UR; Ur+SerPl; Urn; Xylose absorption test |
2.38 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44086-7 |
ABO & Rh group |
Imp |
Bld^Newborn |
Pt |
Nom |
|
|
ACTIVE |
ABO and Rh group [Interpretation] in Blood from Newborn |
|
MIN |
DefinitionDescription |
|
|
|
19057-9, 14908-8, 14580-5 |
|
|
|
|
|
BLDBK |
|
44086-7 |
|
|
|
|
Observation |
|
|
|
0 |
ABO + Rh Bld NB-Imp |
|
|
|
N |
|
ABO + Rh; ABO group and Rh type; ABO+Rh Gp; Blood; BLOOD BANK; D phenotyping; D typing; Hematology; Heme; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; NB; New born; Nominal; Point in time; Random; Rh phenotyping; Rh typing; WB; Whole blood |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44087-5 |
Escherichia coli O157 Ag |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
Escherichia coli O157 Ag [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
E.coli 0157 E.coli 0157:H7 Negative |
|
|
|
|
|
MICRO |
|
44087-5 |
|
|
|
|
Both |
|
|
|
0 |
E coli O157 Ag Spec Ql |
|
|
|
N |
|
Antigen; Antigens; E coli; E coli O157; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; o002; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 44088-3 |
Escherichia coli O157:H7 DNA |
Prid |
XXX |
Pt |
Nom |
Probe.amp.tar |
|
ACTIVE |
Escherichia coli O157:H7 DNA [Identifier] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
E.coli 0157:H7 Positive FOR H7 GENE E.coli 0157:H7 Negative SHIGA TOXIN GENE 1 BOTH SHIGA TOXIN GENES 1 & 2 SHIGA TOXIN GENE 2 |
|
|
|
|
|
MICRO |
|
44088-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
E coli O157H7 DNA Spec NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; E coli; E coli O157; E coli O157H7; Enterohemorrhagic E. coli; ID; Identity or presence; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; o002; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 44089-1 |
Escherichia coli O157:H7 |
Prid |
XXX |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Escherichia coli O157:H7 [Identifier] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
Escherichia coli O157:H7 isolated |
|
|
|
|
|
MICRO |
|
44089-1 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
E coli O157H7 Spec Cult |
|
|
|
N |
|
C&S; Cult; Cultures; E coli; E coli O157; E coli O157H7; Enterohemorrhagic E. coli; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Nominal; o002; Other; Point in time; Random; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4409-9 |
Procainamide |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Procainamide [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4409-9 |
|
|
|
|
Observation |
|
|
|
0 |
Procainamide Dose |
|
|
|
Y |
|
Dose med or substance; DRUG DOSES; PA; Point in time; Procan; Pronestyl; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 44090-9 |
Escherichia coli O157:H7 |
PrThr |
Isolate |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Escherichia coli O157:H7 [Presence] in Isolate by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44090-9 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
E coli O157H7 Islt Ql Cult |
|
|
|
N |
|
C&S; Cult; Cultures; E coli; E coli O157; E coli O157H7; Enterohemorrhagic E. coli; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; o002; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 44091-7 |
Influenza virus A hemagglutinin H5 RNA |
ACnc |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
DEPRECATED |
Deprecated Influenza virus A hemagglutinin H5 RNA [Presence] in Unspecified specimen by Probe & target amplification method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44091-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Deprecated FLUAV HA H5 RNA XXX Ql PCR |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV HA; FLUV; Fowl plague; HA; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.17 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
